Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 6;19:4. doi: 10.1186/s12967-020-02652-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — miR-424 from MSC-derived EVs inhibits the proliferation, migration and tube formation of HUVECs. The HUVECs used for the following detections were treated with MSC-derived EVs, EVs-depleted MSCs, MSC-derived EVs after treatments of miR-424 mimic or miR-424 inhibitor as well as their NCs. a The proliferation of HUVECs after different treatments detected by EdU assay. b The migration of HUVECs after different treatments examined by Transwell assay. c The tube formation of HUVECs after different treatments determined by Matrige-based tube formation assay. d The protein expression of VEGF and VEGFR after different treatments detected by Western blot analysis. *p < 0.05 compared with HUVECs treated with MSC-derived EVs, ^#p < 0.05 compared with HUVECs treated with MSC-derived EVs-mimic-NC; ^&p < 0.05 compared with HUVECs treated with MSC-derived EVs-inhibitor-NC. The data above were measurement data and were presented as sample mean ± standard deviation. Data among multiple groups were compared by one-way ANOVA. The cell experiment was repeated 3 times independently